Egidio Marchi

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Alfa Wassermann, Inc., Biofer S.p.a., Alfa Farmaceutici S.p.a.. Active years: 1979-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Egidio Marchi. Retrieved from https://idiyas.com/inventor/egidio-marchi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 90.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 330(Granted Patents)

Location History:

Casalecchio de Reno, IT (1993)
Bologna, IT (1979 - 1997)
Casalecchio di Reno, IT (1980 - 2021)

Company Filing History:

11 out of 88

Alfa Wassermann, Inc.

Alfa Farmaceutici S.p.a.

patents

Years Active: 1979-2021

Loading Chart...

Areas of Expertise:

Pyrido-Imidazo Rifamycins

Iron Complexes

Glycosaminoglycans

Pharmaceutical Compositions

Diabetic Nephropathy

Biliary Calculosis

Naproxen

Galenic Formulations

Antibacterial Utility

Intramuscular Administration

Low Molecular Weight Complexes

Trivalent Iron

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11028086 - Pyrido-imidazo rifamycins (2021-06-08),

2. 10543216 - Modus of administration of iron, and new formulations adapted for the said goal (2020-01-28),

3. 8993748 - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars (2015-03-31),

4. 8828967 - Low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses (2014-09-09),

5. 8759320 - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars (2014-06-24),

6. 5686432 - Use of some glycosaminoglycans in the peritoneal dialysis (1997-11-11),

7. 5639744 - Bile acids derivatives useful in the therapy of the biliary calculosis (1997-06-17),

8. 5496807 - Method of treatment of diabetic nephropathy by means of sulodexide of (1996-03-05),

9. 5480650 - Programmed release tablets containing naproxen (1996-01-02),

10. 5446152 - Heterocyclic compounds active in gastro-intestinal pathologies (1995-08-29),

11. 5430133 - Semi-synthetic glycosaminoglycans with heparin or heparan structure of (1995-07-04),

12. 5252339 - Pharmaceutical compositions containing orally absorbable (1993-10-12),

13. 5128373 - Packages containing injectable formulations of the sodium salt of (1992-07-07),

14. 5096926 - Injectable formulations containing the sodium salt of naproxen (1992-03-17),

15. 5043167 - Galenic formulations with programmed release (1991-08-27),

Title: The Innovative Mind of Egidio Marchi

Introduction

Egidio Marchi, an accomplished inventor based in Casalecchio di Reno, Italy, has significantly contributed to the fields of pharmaceuticals and biotechnology. With a remarkable portfolio of 20 patents, Marchi has demonstrated a commitment to innovation that addresses pressing healthcare challenges.

Latest Patents

Among his latest innovations, Marchi has developed novel pyrido-imidazo rifamycins, which exhibit highly selective antibacterial activity while minimizing absorption through the oral route. This advancement holds promise for improved antibiotic efficacy with reduced systemic exposure. Additionally, he has introduced a new modus and regimen for the administration of divalent iron, aimed at treating hyposideremia. His formulations are designed to enhance iron absorption through intrabuccal delivery, particularly via sublingual administration, thus reducing toxic side effects associated with traditional methods.

Career Highlights

Egidio Marchi's career is marked by his tenure at notable companies such as Alfa Wassermann S.p.a. and Biofer S.p.a. During his time in these organizations, he has not only honed his expertise in pharmaceutical development but has also played a key role in the advancement of innovative solutions in medication delivery.

Collaborations

Collaboration has been a pivotal aspect of Marchi's success. He has worked alongside esteemed colleagues, including Leone G Rotini and Lauretta Montecchi, sharing knowledge and fostering an environment of innovation. Together, they have contributed to the advancement of various projects that aim to improve health outcomes for patients.

Conclusion

Egidio Marchi exemplifies the spirit of innovation through his dedication to advancing medical science. With a focus on developing effective pharmaceutical therapies, his patents and collaborations have the potential to change how certain conditions are treated, ultimately impacting patient care positively. His work serves as a testament to the critical role inventors play in the evolution of healthcare solutions.

Profile summary based on public USPTO records.